Pallavi Jonnalagadda

Pallavi Jonnalagadda

Auto-generated profile, based on publicly available information

Pallavi Jonnalagadda

The Center for the Advancement of Team Science, Analytics, and Systems Thinking in Health Services and Implementation Science Research (CATALYST), The Ohio State University Wexner Medical Center

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

24 February 2023 in JMIR Medical Informatics
Verified
Journal Article
Open access
DWDaniel M Walker
Daniel M Walker
WTWilli L. Tarver
Willi L. Tarver
PJPallavi Jonnalagadda
Pallavi Jonnalagadda
LRLorin Ranbom
Lorin Ranbom
EFEric Ford
Eric Ford
SRSaurabh Rahurkar
Saurabh Rahurkar
Background: Interoperability—the exchange and integration of data across the health care system—remains a challenge despite ongoing policy efforts aimed at promoting interoperability.Objective: This study aimed to identify current challenges and opportunities to advancing interoperability across stakeholders.Methods: Primary data were collected through qualitative, semistructured interviews with stakeholders (n=24) in Ohio from July to October 2021. Interviewees were sampled using a stratified purposive sample of key informants from 4 representative groups as follows: acute care and children’s hospital leaders, primary care providers, behavioral health providers, and regional health information exchange networks. Interviews focused on key informant perspectives on electronic health record implementation, the alignment of public policy with organizational strategy, interoperability implementation challenges, and opportunities for health information technology. The interviews were transcribed verbatim followed by rigorous qualitative analysis using directed content analysis.Results: The findings illuminate themes related to challenges and opportunities for interoperability that align with technological (ie, implementation challenges, mismatches in interoperability capabilities across stakeholders, and opportunities to leverage new technology and integrate social determinants of health data), organizational (ie, facilitators of interoperability and strategic alignment of participation in value-based payment programs with interoperability), and environmental (ie, policy) domains.Conclusions: Interoperability, although technically feasible for most providers, remains challenging for technological, organizational, and environmental reasons. Our findings suggest that the incorporation of end user considerations into health information technology development, implementation, policy, and standard deployment may support interoperability advancement.

6 May 2024 in WIREs Nanomedicine and Nanobiotechnology
Verified
Journal Article
Open access
MHMaryam Hajfathalian
Maryam Hajfathalian
KMKatherine J. Mossburg
Katherine J. Mossburg
ARAllan Radaic
Allan Radaic
KWKatherine E. Woo
Katherine E. Woo
PJPallavi Jonnalagadda
Pallavi Jonnalagadda
DCDavid P. Cormode
David P. Cormode
Complex metal nanostructures represent an exceptional category of materials characterized by distinct morphologies and physicochemical properties. Nanostructures with shape anisotropies, such as nanorods, nanostars, nanocages, and nanoprisms, are particularly appealing due to their tunable surface plasmon resonances, controllable surface chemistries, and effective targeting capabilities. These complex nanostructures can absorb light in the near‐infrared, enabling noteworthy applications in nanomedicine, molecular imaging, and biology. The engineering of targeting abilities through surface modifications involving ligands, antibodies, peptides, and other agents potentiates their effects. Recent years have witnessed the development of innovative structures with diverse compositions, expanding their applications in biomedicine. These applications encompass targeted imaging, surface‐enhanced Raman spectroscopy, near‐infrared II imaging, catalytic therapy, photothermal therapy, and cancer treatment. This review seeks to provide the nanomedicine community with a thorough and informative overview of the evolving landscape of complex metal nanoparticle research, with a specific emphasis on their roles in imaging, cancer therapy, infectious diseases, and biofilm treatment.This article is categorized under: Diagnostic Tools > In Vivo Nanodiagnostics and Imaging Therapeutic Approaches and Drug Discovery > Nanomedicine for Infectious Disease Diagnostic Tools > Diagnostic Nanodevices

5 August 2020 in Applied Clinical Informatics
Verified
Journal Article
Open access
PDF file
NFNaleef Fareed
Naleef Fareed
CSChristine M. Swoboda
Christine M. Swoboda
PJPallavi Jonnalagadda
Pallavi Jonnalagadda
TGTyler Griesenbrock
Tyler Griesenbrock
HGHarish R. Gureddygari
Harish R. Gureddygari
AAAlison Aldrich
Alison Aldrich
Background An area deprivation index (ADI) is a geographical measure that accounts for socioeconomic factors (e.g., crime, health, and education). The state of Ohio developed an ADI associated with infant mortality: Ohio Opportunity Index (OOI). However, a powerful tool to present this information effectively to stakeholders was needed. Objectives We present a real use-case by documenting the design, development, deployment, and training processes associated with a dashboard solution visualizing ADI data. Methods The Opportunity Index Dashboard (OID) allows for interactive exploration of the OOI and its seven domains—transportation, education, employment, housing, health, access to services, and crime. We used a user-centered design approach involving feedback sessions with stakeholders, who included representatives from project sponsors and subject matter experts. We assessed the usability of the OID based on the effectiveness, efficiency, and satisfaction dimensions. The process of designing, developing, deploying, and training users in regard to the OID is described. Results We report feedback provided by stakeholders for the OID categorized by function, content, and aesthetics. The OID has multiple, interactive components: choropleth map displaying OOI scores for a specific census tract, graphs presenting OOI or domain scores between tracts to compare relative positions for tracts, and a sortable table to visualize scores for specific county and census tracts. Changes based on parameter and filter selections are described using a general use-case. In the usability evaluation, the median task completion success rate was 83% and the median system usability score was 68. Conclusion The OID could assist health care leaders in making decisions that enhance care delivery and policy decision making regarding infant mortality. The dashboard helps communicate deprivation data across domains in a clear and concise manner. Our experience building this dashboard presents a template for developing dashboards that can address other health priorities.

12 December 2023 in JMIR Cancer
Verified
Journal Article
Open access
MGMegan E Gregory
Megan E Gregory
WCWeidan Cao
Weidan Cao
SRSaurabh Rahurkar
Saurabh Rahurkar
PJPallavi Jonnalagadda
Pallavi Jonnalagadda
JSJames C Stock
James C Stock
DADaniel Addison
Daniel Addison
Background: Cardiotoxicity is a limitation of several cancer therapies and early recognition improves outcomes. Symptom-tracking mobile health (mHealth) apps are feasible and beneficial, but key elements for mHealth symptom-tracking to indicate early signs of cardiotoxicity are unknown. Objective: We explored considerations for the design of, and implementation into a large academic medical center, an mHealth symptom-tracking tool for early recognition of cardiotoxicity in patients with cancer after cancer therapy initiation. Methods: We conducted semistructured interviews of >50% of the providers (oncologists, cardio-oncologists, and radiation oncologists) who manage cancer treatment-related cardiotoxicity in the participating institution (n=11), and either interviews or co-design or both with 6 patients. Data were coded and analyzed using thematic analysis. Results: Providers indicated that there was no existing process to enable early recognition of cardiotoxicity and felt the app could reduce delays in diagnosis and lead to better patient outcomes. Signs and symptoms providers recommended for tracking included chest pain or tightness, shortness of breath, heart racing or palpitations, syncope, lightheadedness, edema, and excessive fatigue. Implementation barriers included determining who would receive symptom reports, ensuring all members of the patient’s care team (eg, oncologist, cardiologist, and primary care) were informed of the symptom reports and could collaborate on care plans, and how to best integrate the app data into the electronic health record. Patients (n=6, 100%) agreed that the app would be useful for enhanced symptom capture and education and indicated willingness to use it. Conclusions: Providers and patients agree that a patient-facing, cancer treatment-related cardiotoxicity symptom-tracking mHealth app would be beneficial. Additional studies evaluating the role of mHealth as a potential strategy for targeted early cardioprotective therapy initiation are needed.

1 October 2025 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Open access
SRSaurabh Rahurkar
Saurabh Rahurkar
JOJiayi Ouyang
Jiayi Ouyang
PJPallavi Jonnalagadda
Pallavi Jonnalagadda
XLXiaofu Liu
Xiaofu Liu
SZShijun Zhang
Shijun Zhang
LLLiang Li
Liang Li
Background: Drug safety has historically been understudied in pediatric populations, rendering them “therapeutic orphans.” Pediatric drug indications and dosages are often inferred by extrapolating safety, efficacy, and dosing data from adult studies, leading to widespread off‐label use. However, this approach fails to account for age‐specific differences in disease pathophysiology and developmental pharmacokinetics (PK). Despite evidence that adverse drug events (ADEs) manifest with greater severity in pediatric populations than in adults, fewer than 50% of drugs have been systematically studied for pediatric use. The lack of robust drug safety data may result in suboptimal or harmful treatment strategies.Methods: We used a data‐driven approach that integrated three databases —including Merative MarketScan claims, the Maternal and Pediatric Precision in Therapeutics (MPRINT) Knowledgebase (including 670,185 pediatric pharmacoepidemiology, PK, and clinical trial publications on 5062 drugs), the United States Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS, a postmarketing safety surveillance database), and FDA drug label data— to identify high‐impact target. High‐impact targets were defined as drugs that have a high prescription volume, limited safety evidence and high risk of serious ADEs.Results: With 229,550 prescriptions in MarketScan, only 9 studies, and almost 50 high risk serious ADEs benzonatate was identified as a high‐impact drug of concern. Serious ADEs included seizure, death, and arrhythmia with proportional reportion ratios (PRRs) ranging from 4.3 to 477.8.Conclusion: Approved in 1958, Benzonatate, a nonnarcotic antitussive agent has a limited safety evidence with only nine PE/PK publications in six decades. Moreover, it is frequently prescribed off‐label for cough relief despite questionable effectiveness, and high‐risk of serious ADEs. Our findings reveal a disconnect between clinical practice and suppporting safety evidence. As such, there is critical need to study the safety of this drug using emerging real‐world data for real‐world evidence. In summary, this study presents an approach that is systematic, objective, reproducible, and data driven to identify and prioritize drug‐ADE combinations with limited evidence.